PRESS RELEASE published on 02/29/2024 at 22:05, 2 years 8 months ago Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
PRESS RELEASE published on 02/14/2024 at 13:30, 2 years 8 months ago Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023 Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
PRESS RELEASE published on 12/21/2023 at 14:00, 2 years 10 months ago Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
PRESS RELEASE published on 12/14/2023 at 22:15, 2 years 10 months ago Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRESS RELEASE published on 10/31/2023 at 12:30, 3 years ago Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
PRESS RELEASE published on 10/25/2023 at 13:30, 3 years ago Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
PRESS RELEASE published on 10/17/2023 at 14:00, 3 years ago Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
PRESS RELEASE published on 09/20/2023 at 13:30, 3 years 1 month ago Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Published on 11/14/2026 at 01:30, 5 hours 53 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 6 hours 43 minutes ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 6 hours 48 minutes ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 7 hours 23 minutes ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:15, 8 hours 8 minutes ago Core Critical Metals Corp. Announces $500,000 Non-Brokered Critical Mineral Flow-Through Private Placement
Published on 11/13/2026 at 23:24, 7 hours 59 minutes ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 9 hours 31 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 12 hours 14 minutes ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 12 hours 23 minutes ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 19 hours 48 minutes ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 19 hours 48 minutes ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 23 hours 23 minutes ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 1 day 8 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)